BRIEF

on Credit Suisse Securities (Europe) Limited (isin : CH0406705126)

Sensirion Unveils New Miniature Liquid Flow Sensor Platform for Advanced Drug Delivery

Sensirion AG announced the launch of its new SLD3x series of miniature, digital liquid flow sensors designed specifically for subcutaneous drug delivery, marking a significant innovation in the healthcare sector. The SLD3x platform features customizable sensors that aim to enhance patient safety and ensure precise drug dosing across various therapies.

The healthcare industry is increasingly shifting towards patient-centric solutions such as Large Volume Injectors (LVIs), which facilitate continuous subcutaneous drug delivery. Sensirion’s latest technology supports this transition by integrating high accuracy and miniature size, making it especially suitable for LVIs that require dependable and fine-controlled drug administration. These sensors not only measure flow rates but also detect occlusions, air bubbles, pump malfunctions, and liquid temperatures, contributing to the improvement of patient safety and regulatory compliance.

Dr. Konrad Domanski, Product Director of Liquid Flow Sensors at Sensirion, highlighted that the SLD3x series could cater to a broad range of dosing requirements, with flow rates varying from 100 µl/min to 5 ml/min. This development is aligned with Sensirion’s focus on offering tailored solutions that meet the specific needs of different medical therapies.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Credit Suisse Securities (Europe) Limited news